Early Dapagliflozin and Melatonin Treatment Ameliorated LV Fibrosis via Suppressing TGF‐β1/Smads and Activating Nrf2‐ ARE Signaling in MI Rodent
Open Access
- 2 April 2026
- journal article
- Published by Wiley in The Kaohsiung Journal of Medical Sciences
- Vol. 42 (10) , e70205
Abstract
This study tested whether combined dapagliflozin (DAPA) and melatonin (Mel) therapy was superior to merely one for ameliorating the left ventricular (LV) fibrosis/remodeling and improving LV ejection fraction (LVEF) in rats after acute myocardial infarction (AMI). In vitro study demonstrated that DAPA treatment significantly suppressed the TGF‐β/Smads signaling, whereas Mel treatment significantly upregulated Nrf2/ARE signaling in ischemia–reperfusion (IR) H9C2 cells (all P< 0.001). Additionally, simultaneously silencing TGF‐β and overexpression of Nrf2 in H9C2 cells significantly suppressed fibrotic and upregulated antioxidant signaling (all P< 0.001). Adult male Sprague–Dawley rats were categorized into groups 1 (sham‐operated‐control)/2 (AMI)/3 (AMI + DAPA)/4 (AMI + Mel)/5 (AMI + DAPA‐Mel), and the hearts were harvested by day 28. By day 28 after AMI induction, the LVEF was highest in group 1, lowest in group 2, and significantly higher in group 5 than in groups 3 and 4, but it did not differ between groups 3 and 4, whereas the LV systolic/diastolic dimensions exhibited an opposite pattern of LVEF among the groups (all P< 0.0001). The protein expressions of TGF‐β/Smads signaling exhibited an opposite pattern, whereas the protein expressions of Nrf2/ARE signaling displayed an identical pattern of LVEF among the groups (all P< 0.0001). The protein expressions of oxidative‐stress/DNA‐mitochondria damaged/inflammatory biomarkers and histopathological/anatomical findings demonstrated that the infarct and fibrotic areas/LV‐chamber dimensions/cardiomyocyte size exhibited an opposite manner of LVEF among the groups (all P< 0.0001). In conclusion, combined DAPA‐Mel therapy was superior to merely one for improving LVEF and inhibiting fibrosis/LV remodeling in AMI rodents.Keywords
Funding Information
- Chang Gung Memorial Hospital (CMRPG8L1081)
This publication has 38 references indexed in Scilit:
- Use of Mechanical Circulatory Support Devices Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic ShockJAMA Network Open, 2021
- Myocardial Fibrosis in Heart Failure: Anti-Fibrotic Therapies and the Role of Cardiovascular Magnetic Resonance in Drug TrialsCardiology and Therapy, 2020
- Randomized evaluation of ticagrelor monotherapy after 3-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with new-generation sirolimus-eluting stents: TICO trial rationale and designAmerican Heart Journal, 2019
- Real-World Data of Prasugrel vs. Ticagrelor in Acute Myocardial Infarction: Results from the RENAMI RegistryAmerican Journal of Cardiovascular Drugs, 2019
- Clinical Outcomes at 2 Years Between Beta-Blockade with ACE Inhibitors or ARBs in Patients with AMI Who Underwent Successful PCI with DES: A Retrospective Analysis of 23,978 Patients in the Korea AMI RegistryAmerican Journal of Cardiovascular Drugs, 2019
- Association of the Hospital Readmissions Reduction Program With Mortality Among Medicare Beneficiaries Hospitalized for Heart Failure, Acute Myocardial Infarction, and PneumoniaJAMA, 2018
- Myocardial Fibrosis: Biomedical Research from Bench to BedsideEuropean Journal of Heart Failure, 2017
- Thrombolysis: A Critical First-Line Therapy with an Unfulfilled PotentialThe American Journal of Medicine, 2016
- Comparative Effectiveness of Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors Following Contemporary Treatments in Patients with Acute Myocardial Infarction: Results from the Korean Working Group in Myocardial Infarction (KorMI) RegistryAmerican Journal of Cardiovascular Drugs, 2015
- Role of coronary artery bypass grafting during the acute and subacute phase of ST-elevation myocardial infarctionNetherlands Heart Journal, 2010